Finally, we've decided to move the FDA submission of MONARCH 2 from the previously announced timing of Q3 up in to Q2. And just yesterday we announced that the MONARCH 3 study with abemaciclib met its primary endpoint at an interim analysis, demonstrating that women with HR+, HER2- advanced breast cancer who had not received prior systemic therapy experienced a statistically significant improvement in PFS with treatment with abemaciclib plus an aromatase inhibitor compared to placebo plus an aromatase inhibitor